FDA Actions

March 2009
Travel Medicine Advisor;Mar2009 Supplement, p2
The article reports on a program to be launched by the U.S. Food and Drug Administration in 2009. Said program aims to improve the safety of the country's imported drugs. Under the program, overseas drug manufacturers will be required to apply for certifications that will prove the security of their products' supply chain. It states that the program is in response to concerns over manufacturing processes outside the country and the embargo of foreign manufactured drugs in 2008.


Related Articles

  • FDA Launches Major Review of cGMPs. Wechsler, Jill // Pharmaceutical Technology Europe;Oct2002, Vol. 14 Issue 10, p19 

    Focuses on the conflict between pharmaceutical manufacturers and the U.S. Food and Drug Administration regarding manufacturing practices regulation compliance. Inconsistency of rules enforced by the agency; Plan of the agency to review the current Good Manufacturing Practices; Factors...

  • Pharm Companies Encounter Consequences of Noncompliance.  // Chemical Market Reporter;5/27/2002, Vol. 261 Issue 21, p8 

    Deals with the efforts of the U.S. Food and Drug Administration (FDA) to monitor the manufacturing deficiencies of pharmaceutical companies in the country. Details on the fine paid by Schering-Plough resulting from its failure to comply with the ruling of the FDA; Significance of the effort of...

  • Effort to Protect the Global Supply Chain.  // Pharmaceutical Representative;Jul2011, Vol. 41 Issue 7, p11 

    The article focuses on the move of the U.S. Food and Drug Administration (FDA) to release a new strategy which aims to meet the challenges posed by rapidly rising imports of FDA-regulated products and the increasing complexity of the pharmaceutical supply chain.

  • FDA Actions.  // Neurology Alert;Apr2009 Pharmacology Watch, p2 

    The article discusses the program launched by the U.S. Food and Drug Administration (FDA) to improve the safety of drugs imported to the country. The program would allow drug manufacturers outside the U.S. to apply for certifications. The certifications would require manufacturers to have secure...

  • Understanding the Pharmaceutical Manufacturing Process. Albano, Mark // Pharmaceutical Processing;May2008, Vol. 23 Issue 5, p22 

    The article focuses on the Process Analytical Technology (PAT) initiative by the Food and Drug Administration (FDA) in the U.S. The PAT initiative aims to benefit the pharmaceutical industry by supporting innovation and efficiency in the development and manufacturing of drugs. It focuses on the...

  • The Drug Development Process.  // Pharmaceutical Representative;Feb2011, Vol. 41 Issue 2, p28 

    The article provides an overview of the process involved in the development of a new drug in the U.S. It cites that new drug development involves sequence of stages that can be grouped into phases. It relays that Investigational New Drug (IND) exemption request must be secure from Food and Drug...

  • The Validation Master Plan. Chatterjee, Bikash // Pharmaceutical Processing;Sep2011, Vol. 26 Issue 8, p14 

    The article describes the validation master plan (VMP) and three stages of the U.S. Food and Drug Administration's (FDA) new process validation guidance for pharmaceutical processing. It discusses the three stages of the process validation guidance including process design, process qualification...

  • FDA getting tougher on drug makers.  // Medical Marketing & Media;Aug2001, Vol. 36 Issue 8, p30 

    Presents the stand of the U.S. Food and Drug Administration toward failure of drug makers to comply with good manufacturing practices regulations. Issuance of Warning Letter to violators; Citation of severe regulatory actions; Application of the disgorgement of profits remedy.

  • GMP consent decree with FDA for Lilly. Dickinson, James G. // Medical Marketing & Media;Sep2002, Vol. 37 Issue 9, p30 

    Reports on the good manufacturing practice failures of the pharmaceutical company Eli Lilly in the U.S. Result of the Food and Drug Administration (FDA) inspection; Absence of discussion with the FDA on a consent decree; Problems at the drug manufacturing facility.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics